Alternate sunitinib schedules in patients with metastatic renal cell carcinoma

Annals of Oncology

Volumn 26, Issue 7, 2015, Pages 1300-1304

  Kalra, S ^a   Rini, B I ^b   Jonasch, Eric ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Alternate schedule; Drug administration schedule; Renal cell carcinoma; Sunitinib

Indexed keywords

SUNITINIB; ANGIOGENESIS INHIBITOR; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CLINICAL EFFECTIVENESS; DIARRHEA; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HAND FOOT SYNDROME; HUMAN; KIDNEY METASTASIS; MAXIMUM PLASMA CONCENTRATION; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; CARCINOMA, RENAL CELL; DRUG ADMINISTRATION; KIDNEY NEOPLASMS; PATHOLOGY; PROGNOSIS; SECONDARY;

ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; DRUG ADMINISTRATION SCHEDULE; HUMANS; INDOLES; KIDNEY NEOPLASMS; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRROLES;

EID: 84943768027     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv030     Document Type: Article

References (20)

1. Mittal K, Wood LS, Rini BI. Axitinib in metastatic renal cell carcinoma. Biol Ther 2012; 2: 5.
2. Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27(22): 3584-3590.
3. Motzer RJ, Agarwal N, Beard C et al. NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw 2009; 7(6): 618-630.
4. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356(2): 115-124.
5. Motzer RJ, Hutson TE, Olsen MR et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 2012; 30(12): 1371-1377.
6. Rini BI. Sunitinib. Expert Opin Pharmacother 2007; 8(14): 2359-2369.
7. Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24(1): 25-35.
8. Chow LQM, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007; 25(7): 884-896.
9. Wong MK, Mohamed AF, Hauber AB et al. Patients rank toxicity against progression free survival in second-line treatment of advanced renal cell carcinoma. J Med Econ 2012; 15(6): 1139-1148.
10. Houk BE, Bello CL, Poland B et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/ pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010; 66(2):357-371.
11. Griffioen AW, Mans LA, de Graaf AMA et al. Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin Cancer Res 2012; 18(14): 3961-3971.
12. Powles T, Kayani I, Sharpe K et al. A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer. Ann Oncol 2013; 24(8):2098-2103.
13. Escudier B, Roigas J, Gillessen S et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2009; 27(25): 4068-4075.
14. Barrios CH, Hernandez-Barajas D, Brown MP et al. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer 2012; 118(5): 1252-1259.
15. Najjar YG, Mittal K, Elson P et al. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. Eur J Cancer 2014; 50(6): 1084-89
16. Atkinson BJ, Kalra S, Wang X et al. Clinical outcomes in patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol 2014; 191 (3): 611-618
17. Bjarnason GA, Khalil B, Hudson JM et al. Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature. Urol Oncol 2014; 32(4): 480-487.
18. Neri B, Vannini A, Brugia M et al. Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: a single-center experience with 31 patients. Int J Urol 2013; 20(5): 478-483.
19. Kondo T, Takagi T, Kobayashi H et al. Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma-comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off. Jpn J Clin Oncol 2014; 44(3): 270-277.
20. Rini BI, Melichar B, Ueda T et al. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol 2013; 14(12): 1233-1242.